Skip to main content
Shuttle Pharmaceuticals Holdings, Inc. logo

Shuttle Pharmaceuticals Holdings, Inc. — Investor Relations & Filings

Ticker · SHPH ISIN · US8256933024 US Manufacturing
Open in API
Filings indexed 266 across all filing types
Latest filing 2024-06-18 Board/Management Inform…
Country US United States of America
Listing US SHPH

About Shuttle Pharmaceuticals Holdings, Inc.

https://shuttlepharma.com/

Shuttle Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company focused on developing novel therapies to improve outcomes for cancer patients. The company's mission is to enhance the effectiveness of radiation therapy (RT) by developing drugs that sensitize cancer cells to radiation while protecting adjacent healthy tissues, thereby increasing cure rates and improving quality of life. Its lead product candidate, Ropidoxuridine, is an orally available radiation sensitizer in Phase II clinical development. The pipeline also includes a portfolio of preclinical selective histone deacetylase (HDAC) inhibitors. Additionally, Shuttle is developing diagnostic technologies, including a pretreatment blood test for prostate cancer patients to help predict treatment success and inform therapeutic decisions.

Recent filings

Filing Released Lang Actions
Board/Management Information 2024
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated June 13, 2024, by Shuttle Pharmaceuticals Holdings, Inc. The content focuses on the appointment of a new Chief Financial Officer, Mr. Timothy J. Lorber, including details of his employment agreement and the transition of the current CFO. It also includes a press release about the hiring. The key section is Item 5.02, which relates to the departure and appointment of directors or certain officers. There are no financial statements or detailed financial data presented, nor is this a full annual or quarterly report. The document is primarily an announcement of a management change. Therefore, the appropriate classification is Board/Management Information (MANG). The document length (6760 characters) supports that this is a substantive filing, not a brief announcement or certification, reinforcing the confidence in this classification.
2024-06-18 English
Proxy Solicitation & Information Statement 2024
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A Proxy Statement filed with the SEC, as indicated by the header and form type 'PRE 14A'. It includes detailed information about the upcoming Annual Meeting of Stockholders, including proposals to be voted on, board of directors' biographies, executive compensation, and corporate governance matters. The document is not a full annual report or financial statement but rather materials sent to shareholders to provide information and solicit votes for the annual meeting. This matches the definition of a Proxy Solicitation & Information Statement (PSI). The document length is substantial (15,000 characters), and it contains detailed proxy materials, not just an announcement or a brief notice. Therefore, the correct classification is PSI with high confidence.
2024-06-10 English
Regulatory Filings 2024
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC by Shuttle Pharmaceuticals Holdings, Inc. It includes a Regulation FD Disclosure about the CEO's participation in an investor conference and a webcast presentation. The document references a press release attached as an exhibit and provides forward-looking statements. There are no financial statements or detailed financial data included. The document is primarily an announcement of an event and related disclosures, not a full financial report or earnings release. It is not a report publication announcement since it contains substantive disclosure rather than just a notice of report availability. The best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and miscellaneous filings that do not fit other categories.
2024-05-22 English
Regulatory Filings 2024
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 14, 2024, by Shuttle Pharmaceuticals Holdings, Inc. It reports the issuance of a press release providing a corporate update related to the filing of the Quarterly Report on Form 10-Q for the period ended March 31, 2024. The document itself does not contain the financial statements or substantive financial data but references the press release and the 10-Q filing. The length is 4213 characters, which is relatively short and the document mainly serves as a current report announcing the event rather than the report itself. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories and includes Form 8-K current reports that announce events or updates without containing full financial data.
2024-05-14 English
Interim / Quarterly Report 2024
Interim / Quarterly Report Q1 2024
2024-05-13 English
Regulatory Filings 2024
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated April 29, 2024, by Shuttle Pharmaceuticals Holdings, Inc. It reports an event under Item 8.01 Other Events, specifically announcing the CEO's participation in an investor event and the release of an updated investor presentation. The presentation is attached as Exhibit 99.1. The document explicitly states that the information, including the presentation, is furnished and not filed, and it is not to be considered as part of the company's formal filings. The content is primarily an announcement of an investor presentation rather than the presentation itself or a detailed financial report. The document length is 6718 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this filing is best classified as a Regulatory Filing (RNS), as it does not contain substantive financial data or the full investor presentation text but announces its availability and related event information.
2024-04-29 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.